Horizon Discovery to host CRISPR Screening Webinar: “How gene editing is becoming embedded in drug discovery workflows at an industrial scale”

Cambridge, UK, 18 October 2018: Horizon Discovery Group plc (LSE: HZD) ('Horizon' or 'the Group'), a global leader in the application of gene editing and gene modulation technologies, will host a CRISPR Screening Webinar for investors and sell-side analysts between 15:00 - 16:00 GMT / 10:00 - 11:00 ET on Wednesday 7 November 2018.

The nature of drug discovery is changing as global pharmaceutical and biotech companies face rising R&D costs and diminishing returns. The availability of CRISPR screening has revolutionised the possibilities of scientific insight via the quality and quantity of data that can be generated and now means that gene editing is becoming embedded in drug discovery workflows at an industrial scale.

This webinar will showcase and explain how Horizon is driving the availability and uses of this novel technological solution for pharmaceutical and biotech companies, from both the Group's and customers' perspectives. The session will address this need and will cover Horizon's, and the wider market's, rapid adoption of CRISPR screening and provide an overview of its broad applicability across drug discovery, including:

• Identifying drug targets
• Profiling existing drugs
• Supporting patient stratification
• Understanding drug-gene interaction

The webinar will be followed by a Q&A session.

Please contact [e-mail] if you would like to attend. Log-in details for the webinar will be provided in advance of the event.